Basics Allogene Therapeutics, Inc. IPO Date: October 8, 2018 Sector: Healthcare Industry: Biotech Market Cap: $253.73M Activated in VL: True Average Daily Range Avg Daily Range: $0.47 | 3.11% Avg Daily Range (30 D): $0.07 | 5.00% Avg Daily Range (90 D): $0.08 | 4.88% Institutional Daily Volume Avg Daily Volume: 1.44M Avg Daily Volume (30 D): 3.37M Avg Daily Volume (90 D): 4.37M Trade Size Avg Trade Size (Sh.): 132 Avg Trade Size (Sh.) (30 D): 320 Avg Trade Size (Sh.) (90 D): 291 Institutional Trades Total Inst.Trades: 2,887 Avg Inst. Trade: $1.87M Avg Inst. Trade (30 D): $1.27M Avg Inst. Trade (90 D): $1.31M Avg Inst. Trade Volume: .17M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.45M Avg Closing Trade (30 D): $.8M Avg Closing Trade (90 D): $1.87M Avg Closing Volume: 229.17K         News Mar 5, 2025 @ 6:00 PM CAR T-cell Therapy Clinical Trial Pipeline Experie... Source: Delveinsight Dec 26, 2024 @ 4:26 PM Oncology in Focus: How Emerging Therapies Are Resh... Source: Prnewswire Oct 22, 2024 @ 5:00 PM Gene Therapy Clinical Trial Pipeline Gains Momentu... Source: Delveinsight Sep 10, 2024 @ 8:51 AM Gene Editing Therapeutics Market Forecast 2024-202... Source: Researchandmarkets.Com Jul 1, 2024 @ 12:30 PM Allogene Therapeutics Activates Three Community Ca... Source: Allogene Therapeutics, Inc. Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.23 $-.28 $-.28 Diluted EPS $-1.23 $-.28 $-.28 Revenue $ M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -252.32M $ -59.73M $ -59.94M Operating Income / Loss $ -268.89M $ -65.19M $ -60.49M Cost of Revenue $ $ $ Net Cash Flow $ -8.58M $ -32.76M $ 23.98M PE Ratio